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Abstract
The quantitative analysis of Plasmodium development in the liver in laboratory animals in cultured cells is hampered by low
parasite infection rates and the complicated methods required to monitor intracellular development. As a consequence, this
important phase of the parasite’s life cycle has been poorly studied compared to blood stages, for example in screening anti-
malarial drugs. Here we report the use of a transgenic P. berghei parasite, PbGFP-Luccon, expressing the bioluminescent reporter
protein luciferase to visualize and quantify parasite development in liver cells both in culture and in live mice using real-time
luminescence imaging. The reporter-parasite based quantification in cultured hepatocytes by real-time imaging or using a
microplate reader correlates very well with established quantitative RT-PCR methods. For the first time the liver stage of
Plasmodium is visualized in whole bodies of live mice and we were able to discriminate as few as 1–5 infected hepatocytes per
liver in mice using 2D-imaging and to identify individual infected hepatocytes by 3D-imaging. The analysis of liver infections by
whole body imaging shows a good correlation with quantitative RT-PCR analysis of extracted livers. The luminescence-based
analysis of the effects of various drugs on in vitro hepatocyte infection shows that this method can effectively be used for in vitro
screening of compounds targeting Plasmodium liver stages. Furthermore, by analysing the effect of primaquine and
tafenoquine in vivo we demonstrate the applicability of real time imaging to assess parasite drug sensitivity in the liver. The
simplicity and speed of quantitative analysis of liver-stage development by real-time imaging compared to the PCR
methodologies, as well as the possibility to analyse liver development in live mice without surgery, opens up new possibilities
for research on Plasmodium liver infections and for validating the effect of drugs and vaccines on the liver stage of Plasmodium.
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Introduction
Malaria remains a major cause of global morbidity and
mortality. New anti-malarial drugs are urgently needed,
especially with the increase in drug resistant parasites and the
lack of effective vaccines and vector control measures [1–4]. The
main site for intracellular development of human and rodent
Plasmodium sporozoites after they are injected by an infected
mosquito is the liver. This stage of the parasite’s development is
clinically silent and therefore regarded as an ideal point of
intervention for prophylactic or vaccine strategies [5–7]. The
liver stage of Plasmodium’s life cycle has also received particular
attention in the context of P. vivax, the second most important
agent of human malaria, which can generate cryptic forms called
hypnozoites that persist in the liver for long periods of time [8–
10]. These dormant forms of the parasite are responsible for what
is termed relapsing malaria, which may occur following latent
periods of months or even years without new infection [10,11]. In
comparison with drugs that kill blood stage parasites, only a
limited number of drugs exist that act on liver stages; most
notable amongst these are primaquine, atovaquone and tafeno-
quine [12,13], and only primaquine [14,15] has been shown to
act on the hypnozoite stage of P. vivax [14,15]. Clearly, the
development of new inhibitors/drugs against the malaria liver
stage would target an important and under-exploited site of
intervention [1,16].
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Quantitative analysis of liver stage Plasmodium development both
in vivo in laboratory rodents and in vitro in cultured liver cells is
hampered by the low levels of parasite infection and by the
complicated methods required to monitor parasite development. As
a consequence, the development of novel and efficient methods for
analysing/screening the effect of drugs and small molecule
inhibitors on the parasite’s intracellular growth in the liver lags
well behind the more rapid developments being made in the
automated drug/inhibitor screening assays for blood stage parasites
[17–20]. Currently, one of the standard ways to assess drug efficacy
against liver stages is to monitor in vitro liver stage development by
quantitative RT-PCR (qRT-PCR) methods [21–23] [24,25] that
are time consuming and expensive. Other studies have involved
direct quantification and viability of parasite development by
microscopy [26,27], RNA hybridization [28], or infrared fluores-
cence scanning system [29]. However, these methods are not only
prone to large variations between observers but are also time
consuming given the very low infection rates (generally less than 2%)
observed in cultured hepatocytes [29]. Moreover, simple and
efficient methods for analysing in vivo liver stage development in
small laboratory animals are completely absent. The recent
generation of new transgenic rodent malaria parasites expressing
fluorescent reporter proteins has enabled an intimate analysis of
Plasmodium sporozoites interacting with host hepatocytes during
invasion and subsequent development inside hepatocytes, both in
vitro and in vivo [30–34]. Recently, GFP-expressing parasites have
been used in conjunction with flow cytometry to provide
quantitative information on the parasites development in hepatic
cells [35]. However, the use of fluorescent parasites in in vivo analysis
of Plasmodium liver stage development requires complex surgery and
when such parasites are used in conjunction with flow cytometry,
their usefulness is presently restricted to in vitro and ex vivo analyses.
We have previously reported the use of transgenic P. berghei
parasites expressing the bioluminescent reporter protein, lucifer-
ase, to examine the distribution and development of sequestering
blood stage parasites in live animals using real time imaging
[36,37]. Recently, we have also shown the effectiveness of such
bioluminescent reporter parasites in simple and sensitive micro-
plate reader assays for screening of drugs against blood stage
parasites both in vitro and in vivo in rodents [19]. For these assays we
generated a transgenic P. berghei parasite line that expresses a
luciferase-GFP fusion protein and is free of a drug-selectable-
marker [38]. In the study described here, we utilised the
luminescent properties of this reporter parasite, PbGFP-Luccon,
to analyse liver stage development by real time imaging both in
cultured hepatocytes and within the liver of living mice. We
established that the changes in bioluminescence are directly
proportional to the level of hepatocyte infection in vitro and in vivo,
determined by comparison with standard qRT-PCR methodolo-
gies. As the liver parasite infection progresses real-time in vivo
imaging allows the identification of individual infected hepatocytes
in living animals. We demonstrated the application of the
technique for the in vitro screening of compounds targeting the
liver stage and the use of real-time imaging to determine in vivo
drug sensitivity of liver stages through analysis of the effect of
primaquine. Importantly, bioluminescence imaging also allows the
course of an infection to be monitored, both throughout liver stage
parasite development and in the blood stage of infection without
sacrificing the animal, and therefore, can greatly reduce the
number of experimental animals required to determine drug
sensitivity. Since bioluminescence imaging is relatively simple to
execute, the use of the methodologies described in this paper will
greatly simplify the analysis of drug toxicity and small molecule
inhibition on liver stage parasite growth.
Materials and Methods
Experimental animals
Female C57BL/6 and Swiss CD1 mice, 6–8 weeks old (Charles
River), weighing 20 to 35 g at the time of primary infection and
female Wistar rats (Harlan; 175–200 g) were used.
All studies in which animals were involved have been performed
according to the regulations of the Dutch ‘‘Animal On
Experimentation act’’ and the European guidelines 86/609/EEG.
Transgenic parasite line
The transgenic P. berghei line 676m1cl1 line (PbGFP-Luccon) has
been used in this study (mutant RMgm-29 in www.pberghei.eu). It
expresses a fusion GFP (mutant 3) and firefly luciferase (LucIAV)
and has been generated in the reference clone of ANKA strain
cl15cy1 [38]. Parasites of line 676m1cl1 contain the PbGFP-Luc
gene fusion stably integrated as a single copy gene by double cross
over recombination into the 230p locus and the reporter gene is
under control of the constitutive eef1aa promoter [39]. This line
has been selected by FACS-sorting of GFP-expressing parasites
and therefore does not contain a drug-selectable marker. This line
can be obtained from the Malaria Research and Reference
Reagent Resource Center, MR4 (http://www.malaria.mr4.org).
Collection of sporozoites
Anopheles stephensi mosquitoes were infected by feeding on
infected mice using standard methods of mosquito infection. On
day 21–28 after infection, the salivary glands of the mosquitoes
were collected by hand-dissection. Salivary glands were collected
in DMEM (Dulbecco’s Modified Eagle Medium from GIBCO)
and homogenized in a home made glass grinder. The free
sporozoites were counted in a Bu¨rker-Tu¨rk counting chamber
using phase-contrast microscopy.
Sporozoites traversal and gliding
Traversal assays were performed as described previously [40].
Briefly, Huh7 cells were plated in 24 well plates (104 cells/ml) and
an equivalent number of sporozoites was added to the wells with
the addition of FITC labeled dextran (Invitrogen, NL). No
sporozoites were added to the negative control wells that were used
as threshold for the FACS analysis. FACS analysis was performed
on 25 000 cells per well (wells were prepared in triplicate) using a
FACScalibur flowcytometer (Becton Dickinson, NL).
Gliding assays were performed in precoated (3D11, 10 ug/ml)
Labtek slides (Nunc, NL) and 26104 sporozoites were added. After
30 minutes of incubation at 37uC sporozoites were fixed with 4%
PFA and after washing with PBS, the sporozoites and the trails
(‘gliding circles’) were stained with 3D11-Alexa 488 conjugated
antibody (Dylight 488 antibody labelling kit; Thermo Scientific,
NL). Slides were mounted with Fluoromount-G (SouthernBiotech,
NL) and ‘gliding circles’ were analyzed using a Leica DMR
fluorescence microscope at61000 magnification.
In vitro development of liver stages in hepatocyte
cultures
To measure the luciferase activity of liver stages in HepG2 cells,
a total of 26104 to 1.56105 sporozoites were added to monolayers
of 26105 HepG2 cells (1 ml/well in 24 well plates) as described
previously [41]. Cells were prepared in quadruplet wells. In several
assays, Cytochalasin D (Sigma, NL) was added to the cells at a
concentration of 10 mg/ml prior to addition of the sporozoites as
previously described [42]. At different time points after invasion,
100 ml of cells were collected, transferred to 96-well plates and
Imaging of Malaria Liver Stage
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processed for imaging with the Lumina system (see below). Four
hundred ml of the remaining cells were harvested and lysed with
either 200 ml of RLT buffer (RNA easy kit, Quiagen, NL) or
200 ml of cell culture lysis reagent obtained from the Promega
Luciferase Assay System KitH (Promega, NL) and stored at280uC
until further analysis by qRT-PCR or bioluminescence with a
microplate reader(see below).
To measure the luciferase activity of liver stages in Huh7 cells a
total of 56103 to 76104 sporozoites were added to triplicate wells
containing monolayers of 76104 Huh7 cells (400 ml/well in 24
well plates) as previously described [35]. At different time points
after sporozoite addition, cells were harvested and lysed with either
150 ml of qRT-PCR buffer (RNA easy kit, Quiagen, NL) or 100 ml
of cell culture lysis reagent obtained from the Promega Luciferase
Assay System KitH (Promega, PT). Samples in Promega lysis
buffer were either stored at 280uC or processed immediately to
measure luminescence intensity with the Lumina system (see
below) or bioluminescence analysis by microplate reader (see
below) and qRT-PCR samples were stored at 280uC until further
analysis by qRT-PCR analysis (see below).
Real time measurements of bioluminescence of in vitro
cultured liver stages using the Lumina system
The in vivo imaging system Lumina (Caliper Life Sciences, USA)
was used to measure luciferase activity of infected HepG2 and
Huh7 cells. Imaging data were analysed using the Living ImageH
3.0 software (Caliper Life Sciences, USA). For the infected HepG2
cells, 100 ml of Assay Substrate (Promega Luciferase Assay System
KitH) were added to 100 ml of hepatocyte cultures collected in 96-
well plates (see above) and bioluminescence images were acquired
with a 12,5 cm field of view (FOV), medium binning factor and an
exposure time of 1 to 3 minutes. For infected Huh7 cells, 70 ml of
Luciferase Assay Substrate (Promega Luciferase Assay System
KitH) were added to 20 ml of lysed hepatocyte cultures in black 96-
well plates. Bioluminescence images were acquired with a 12,5 cm
FOV, medium binning factor and an exposure time of 5 minutes.
Bioluminescence measurements of in vitro cultured liver
stages using a microplate reader (luminometer)
For infected HepG2 cells, 100 ml of Luciferase Assay Substrate
(Promega Luciferase Assay System KitH) were added to 10 ml of
lysed parasite samples in 96-well plates. Luminescence spectra of
the samples were measured using a microplate reader (Wallac
1420 multilabel counter, PerkinElmer, NL) and the light reaction
of each well was measured for 10 s. Measurements of luciferase
activity are expressed as relative luminescence units (RLU). For
infected Huh7 cells, 75 ml of Luciferase Assay Substrate (Promega
Luciferase Assay System KitH) were added to 15 ml of lysed
parasite samples in white 96-well plates. Luminescence intensity of
the samples was measured using a microplate reader (Tecan, CH)
and the light reaction of each well was measured for 5 seconds.
Measurements of luciferase activity are expressed as relative
luminescence units (RLU).
In vivo development of liver stages in mice
Mice were inoculated with sporozoites by i.v. injection of
16103, 16104, 56104 or 16105 purified sporozoites or by
mosquito bite (5–10 infected mosquitoes per mouse) at day 20–
22 after the infectious blood meal. Blood stage infections were
monitored by analysis of Giemsa-stained blood smears of tail blood
collected on day 4–10 after inoculation of sporozoites or infection
by mosquito bite.
Real time in vivo imaging of liver stage development in
whole bodies of live mice or in dissected livers
Luciferase activity in animals was visualized through imaging of
whole bodies or of dissected livers using the in vivo Imaging System
(IVIS 100 and Spectrum; Caliper Life Sciences, USA) as described
in Franke-Fayard et al. [37]. Animals were anesthetized using the
isofluorane-anesthesia system (XGI-8, Caliper Life Sciences,
USA), their belly was shaved and D-luciferin dissolved in PBS
(100 mg/kg; Synchem Laborgemeinschaft OHG, Germany) was
injected subcutaneously (in the neck). Animals were kept
anesthetized during the measurements, which were performed
within 3 to 5 minutes after the injection of D-luciferin.
Bioluminescence imaging was acquired with a 10 cm FOV,
medium binning factor and an exposure time of 10 to 180 seconds.
Luciferase activity in individual livers was visualized in whole
organs dissected 44 h after sporozoite injection or mosquito bite.
Livers were obtained by dissection of animals 2 to 3 min after a
second intravenous injection of D-luciferin (in the tail vein;
100 mg/kg). Livers were placed in Petri-dishes or on black tape to
minimize light interference from plastic Petri-dishes. Dissected
livers were imaged with a 10 cm FOV, medium binning factor
and an exposure time of 60 to 180 seconds. Imaging data were
analysed using the Living ImageH 3.0 (Caliper Life Sciences, USA)
software.
Quantitative analysis of bioluminescence of whole bodies or
dissected livers was performed by measuring the luminescence
signal intensity using the ROI settings of the Living ImageH 3.0
software. The ROI was set to measure either the abdominal area
at the location of the liver for whole body imaging or the complete
livers in the case of dissected livers. ROI measurements are
expressed in total flux of photons.
For the 3D imaging of luciferase activity in live mice, the in vivo
imaging system IVISH 3D (Caliper Life Sciences, USA) was used
as described [43–45]. The IVISH 3D performs rotational axis
imaging of the bioluminescent light sources within a living animal.
The IVIS 3D acquires eight imaging views about the longitudinal
axis of the animal at 3 different wavelengths: 580, 600 and
620 nm. At each angle view, the animal height or surface
topography is determined and stitched together to generate the
whole 3D map of the animal. The 3D diffuse tomography software
(Living Image TM) is used to reconstruct the eight bioluminescent
images resulting in data on in vivo source brightness, location, and
size of the infection. Exposure time was of 60 seconds for each
angle of measurements. A digital female mouse atlas was overlaid
onto the 3D diffuse tomography reconstruction to obtain
anatomical reference points. This feature is included in the Living
Image Software 3D Analysis Package. The liver was removed from
the 3D reconstruction of the mouse organs to better visualize the
bioluminescence signals.
Analysis of in vitro development of liver stages in
hepatocyte cultures and in extracted livers by qRT-PCR
RNA was extracted from hepatocyte culture samples collected
in 200 ml (HepG2) or 150 ml (Huh7) of qRT-PCR buffer (see
above) with Quiagen’s MicroRNeasy kit following the manufac-
turer’s instructions. The transcriptor first-strand cDNA synthesis
kit (Roche) was used according to the manufacturer’s recommen-
dations to make single-stranded cDNA. RNA was extracted from
livers collected at 44 h after infection and homogenized in RLT
buffer (DNA/RNA Quiagen extraction kit) supplemented with
0,07% b-mercaptoethanol and stored at 280uC till qRT-PCR
analysis. The RNA samples were further processed as described
above for the samples of the hepatocyte cultures.
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Real time PCR analysis of specific P. berghei parasite 18S rRNA
and b actin mouse (HepG2 invasion) or Hypoxanthine Guanine
Phosphoribosyl Transferase (HPRT; Huh7 invasion and whole
infected livers) housekeeping genes was done according to [21,35].
Standardization was done by multiplying the value of each sample
with a correction factor. This correction factor is the maximum
value for the housekeeping genes found for all samples divided by
the value of this gene obtained for the sample).
Analysis of drug-inhibition of in vitro liver stage
development
For the analysis of inhibition of in vitro liver stage development
by drugs, 36104 sporozoites were added to monolayers of 76104
Huh7 cells (400 ml/well) in 24 well plates as described above. Five
drugs that are known to inhibit liver stage development were used
to test the drug susceptibility: primaquine (primaquine diphos-
phate 98%, Aldrich, NL); tafenoquine (GlaxoSmithKline, UK);
genistein [25]; lopinavir [24] and saquionovir [24]). Primaquine
was dissolved in water to a final stock solution of 100 mM and
serial dilutions with complete culture medium were prepared
ranging from 1 mM to 100 mM. Tafenoquine was dissolved in
ethanol to a final stock concentration of 100 mM and serial
dilutions were prepared ranging from 0,3 to 30 mM. Genistein,
lopinavir and saquinavir were dissolved in water to a final stock
concentration of 100 mM, 100 mM and 25 mM, respectively. Serial
dilutions with complete culture medium were prepared, ranging
from 10 to 100 mM for genistein and 2,5 to 40 mM for lopinavir
and saquinovir. Huh7 cells were incubated with different
concentrations of the drugs in triplicate wells by replacing the
culture medium with drug-containing medium prior to sporozoite
addition. Forty-six hours after adding the sporozoites, the infected
Huh7 cells were harvested and lysed with 100 ml of cell culture
lysis reagent obtained from the Promega Luciferase Assay System
KitH. Seventy-five ml of Luciferase Assay Substrate (Promega
Luciferase Assay System KitH) were added to 15 ml of lysed
parasite samples in white 96-well plates. Luminescence spectra of
the samples were measured using a microplate reader (Tecan, CH)
and the light reaction of a sample of each well is measured for 5
seconds. Measurements of luciferase activity are expressed as
relative luminescence units (RLU).
Analysis of the inhibition of in vivo liver stage
development by primaquine and tafenoquine
Mice were treated with primaquine (primaquine diphosphate
98%, Aldrich, NL) and tafenoquine (GlaxoSmithKline, UK) once
at day21, twice on the day of infection (day 0; 5 hours before and
after infection) and once the following day (day +1; 19 h and 29 h
after infection). Both primaquine and tafenoquine were dissolved
in distilled water and administered subcutaneously with concen-
trations ranging from 1–40 mg/kg body weight and 10 and
20 mg/kg body weight respectively. Mice were infected at day 0
by the bite of 5–10 mosquitoes, as described above. In vivo imaging
was performed at 44 hours after infection as described above. At
day 6 – 9 after infection, the same mice were analysed for blood
stage infections by determination of the course of parasitemia in
Giemsa stained thin blood films of tail blood.
Growth inhibitory curves and statistical analysis
The two tailed analysis using the Spearman’s rho test of the
SPSS 16 software (SPSS Inc., USA) was used for statistical
analysis. Correlation coefficients were determined using the two-
tailed Spearman’s rho test for non-parametric analysis of small
data set. qRT-PCR curves were drawn using the GraphPad Prism
software (GraphPad Prism, Inc., US). p values were calculated
using the same GraphPad Prism software. The non-linear
regression function for sigmoidal dose-response (variable slope)
of the GraphPad Prism software was used to calculate the (best-fit)
effective concentration (EC50) values.
Results
Analysis of PbGFP-Luccon liver-stage development in vitro
For the analysis of liver stage development we used a transgenic
P. berghei parasite, PbGFP-Luccon (line 676m1cl1), which expresses
a reporter fusion gene of gfp and luciferase, stably integrated in the
230p locus (PB000423.03.0) of the P. berghei genome. PbGFP-
Luccon parasites do not contain a drug-resistance marker as they
were selected by FACS sorting of transfected GFP-positive blood
stages immediately after the transfection procedure [38]. The gfp-
luciferase transgene in PbGFP-Luccon is under the control of the P.
berghei eef1a promoter. Through the analysis of GFP expression we
have previously demonstrated that the eef1a promoter drives
constitutive and strong gene expression in all life cycle stages,
including liver stage parasites [39]. The blood and mosquito stages
of PbGFP-Luccon show similar growth characteristics as those of
the parent reference line, cl15cy1 of P. berghei ANKA (data not
shown). Analysis of sporozoite motility, cell traversal and in vitro
and in vivo infectivity demonstrated that all features of PbGFP-
Luccon sporozoites were comparable to those of wild type
sporozoites (Figure S1).
To determine the timing and level of luciferase expression of
PbGFP-Luccon throughout development of liver stages in vitro, two
hepatoma cell lines, HepG2 and Huh7, were infected with
different numbers of sporozoites, ranging from 56103 to 1.56105,
in 24-well plates. The time course of luciferase expression during
the first 48 hours of development is shown in Figures 1A&B and
S2A&B. The luminescence intensity (luciferase activity) was
measured by (a) direct imaging of the culture plates of live or
lysed cells using the Lumina system (the luminescence intensity
expressed as photons per second) or by (b) analysis of lysed cell
samples in a microplate reader (luminescence intensity expressed
as Relative Light Units, RLU). Both methods show a strong
increase in luciferase activity throughout the 48 h period during
which the invaded sporozoites develop into liver schizonts. The
increase in reporter protein expression during trophozoite and
schizont development is expected as a similar increase in eef1a
based expression of luciferase or GFP is observed in blood stage
trophozoites and schizonts [19,36]. Uninfected control cells
showed low photon counts and luminescence values are
significantly lower than those of infected cells at any of the time
points assessed The mean photon counts were 36106 p/s (sd
26106) and 56104 p/s (sd 16103) and the mean RLU values were
56 (sd 17) and 30 (sd 15) for HepG2 and Huh7 cells respectively.
Sporozoites contain low levels of the GFP-Luciferase protein as
shown by analysis of GFP expression by fluorescence-microscopy
(data not shown) and therefore low bioluminescence levels at 4–
5 h might be derived from invaded sporozoites. A strong increase
in luminescence values is observed after 24–30 h which correlates
with the development of the liver trophozoite into the schizont
stage. For further quantitative analyses of liver stage development
we compared luminescence levels of samples taken at time points
between 30 and 48 h after sporozoite incubation.
Luminescence intensities at 30 and 48 h correlate well with the
number of sporozoites added to the hepatocytes in the range of
56103 to 16105, using both the Lumina and the microplate
reader (Figures 1C, S2A–C). When using as few as 56103
sporozoites a clear luminescent signal is obtained that is
Imaging of Malaria Liver Stage
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Figure 1. Analysis of in vitro liver stage development by determination of luciferase expression (luminescence). A. Luminescence levels
(photons/sec) during liver stage development of PbGFP-Luccon after infection of Huh7 cells with different numbers of sporozoites at 48 h (left panel)
and at different time points after infection with 36104 sporozoites (right panel) determined by direct imaging of samples using the Lumina system.
Rainbow images show the relative levels of luminescence ranging from low (blue), to medium (green), to high (yellow/red). B. Luminescence levels
during development of liver stages at different time points after invasion of Huh7 cells as measured by the Lumina system (Photons/sec) and a Tecan
microplate reader (Relative light unit, RLU). C. Relationship between the numbers of sporozoites used to infect Huh7 hepatocyte cultures and the
luminescence produced by the liver stages at 48 h after infection. Luminescence levels were determined by direct imaging of samples using the
Lumina system (Photons/sec) and a Tecan microplate reader (RLU). D. Correlation between luminescence values as measured by the Lumina system
and the Tecan microplate reader and of P. berghei 18S rRNA levels as determined by qRT-PCR of Huh7 cultures that are infected with different
numbers of sporozoites. See Table S1 for the correlation coefficient data of the two-tailed Spearman’s rho test.
doi:10.1371/journal.pone.0007881.g001
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significantly higher than the background signal detected in
uninfected wells (p = 00,1). We then compared the relative
luminescence intensities of cells infected with different sporozoite
numbers with the relative amounts of parasite 18S ribosomal RNA
using standard qRT-PCR methodologies (Figures 1D, S2D). A
good correlation was observed between the relative luminescence
intensities and the relative amounts of parasite 18S rRNA in the
same cultures (Spearman correlation coefficient ranging from
0.61–0.94; Table S1).
Analysis of PbGFP-Luccon liver-stage development in vivo
To determine the timing and level of luminescence during
PbGFP-Luccon development in the liver, groups of mice (n = 4)
were infected intravenously with different numbers of sporozoites
ranging from 16103 to 16105. Luciferase activity in the animals
was visualized through the imaging of whole bodies using the
IVIS100 imaging system at 5, 24, 35 and 44 hours after infection.
In control, uninfected mice, luminescence values ranged between
16107 and 46107 p/s (sd 16107). In mice infected with the
highest dose of sporozoites (i.e. 16105), 3 mice showed
luminescence levels above background at 24 h (i.e. 16108 p/s
(sd 36107); see Figure 2A&B). Mice infected with 56104
sporozoites showed a signal above background at 35 h. In all
infected mice there was a strong increase in bioluminescence signal
between 35 and 44 h (Figures 2C, S3) whereas between 44 h and
52 h no further increase was observed and, indeed, in several mice
the luminescence signal decreased between these time-points
(Figure S4A). After 60 h, luminescence signals could be detected in
the whole body, resulting from parasites that had invaded
erythrocytes after the rupture of the liver schizonts (Figure S4A).
The decrease in luminescence in the liver between 44 and 52 h
may either be due to liver schizont rupture and the consequent
reduction in the number of infected liver cells or is the results of
decrease in luciferase expression in the final stages of schizont
maturation. Such a decrease has been previously observed in
erythrocytic schizonts where protein expression peaks in mature
trophozoites/young schizonts and decreases in maturing schizont
when the eef1a promoter is used to drive protein expression [36,39]
and correlates with destruction of endogenous eef1a mRNA in
schizonts [46]. Based on these observations, we decided to
determine luminescence intensities at 44 h in subsequent exper-
iments. When luminescence intensities were measured at 44 h, a
good correlation was observed between the luminescence intensity
and the number of sporozoites initially injected (Figures 2D&E).
Specifically, the mean luminescence intensity of mice infected with
16103 sporozoites was 16109 p/s (sd 46108) and increased to
161010 p/s (sd 76109) in mice infected with 16104 sporozoites.
After the whole body measurements, the livers of several of the
mice from each group were dissected and imaged with the
IVIS100 system. The luminescence intensity of the extracted livers
was significantly lower than that of whole bodies (Figures 2C&D,
S3). For example, livers from mice infected with 16105 sporozoites
had, on average, a ten-fold lower luminescence signal compared to
whole body imaging (86108 p/s, sd 46108; Figure 2D). The
presence of clearly separated luminescent spots in dissected livers
of mice infected with low numbers of sporozoites (16103;
Figures 2C, S3) indicates that these spots represent individual
liver schizonts. Therefore, imaging of dissected livers may provide
information on both the number and dissemination of parasites in
the liver. When livers containing 3 to 13 individual spots were
imaged, both sides often showed a comparable numbers of spots in
a similar location (Figures S3B, S4B). However in each liver
imaged, one or a few luminescent spots were only visible on one
side of the liver, indicating that the imaging of these spots can be
influenced by their localization, possibly due to a quenching effect
of the liver. To better localize the origin of individual luminescent
spots, we used the IVIS 3D Series system (Caliper Life Sciences,
USA) to image luminescent signals in live mice in three
dimensions. This instrument, in combination with the 3.1 Living
ImageH software, allows the precise localization of the origin of the
luminescent signals in whole bodies in contrast to the more diffuse
luminescence signals obtained with the IVIS100 2D-system. 3D-
imaging of 4 infected mice in an anatomical context show the
presence of clearly separated spots in the liver (Figures 2F and S5).
The individual infected hepatocytes can be best visualized in the
context of the whole liver when the mice are rotated as visualized
in the Supplementary movies S1-S3. When the number of
luminescent spots was determined by 2D-imaging in livers
dissected after the 3D-imaging of the whole mice, a good
correlation between the numbers of spots obtained with both
methods was found. These observations indicate that 3D-imaging
of whole bodies allows the detection of individual liver schizonts in
live mice. However, like in 2D-imaging of isolated livers, some
luminescent spots may be missed in the 3D-imaging, as shown in
mouse 4 Figure S5.
As described for the in vitro analysis of liver stage development,
we compared the relative luminescence intensities of whole bodies
and isolated livers measured at 44 h pi with 18S ribosomal RNA
qRT-PCR data derived from RNA extracted from the same livers.
The relative luminescence intensities of whole bodies and dissected
livers are in good agreement with the 18S rRNA qRT-PCR values
(i.e. Spearman correlation coefficient ranging from 0.65 to 0.95;
Figure 2E, Table S2). The best correlation is found between qRT-
PCR and whole body imaging, possibly because of the decrease of
luminescence during extraction of the livers as discussed above.
Rats (e.g. Sprague-Dawley, Wistar etc) as well as mice are
frequently used to analyse liver stage development in the P. berghei
model of malaria. We have performed a limited number of
experiments to investigate whether in vivo imaging of liver stage
development in Wistar rats generates similar results to the in vivo
imaging in mice (Figure S4B). In rats luminescence signals were
detected at 24 h after infections had been initiated by mosquito
bite with rapidly increasing luminescence intensities during the
period of 24–30 h. Imaging of dissected livers from these rats also
showed the same pattern of clearly separated luminescent spots (on
both sides of the liver) as we had observed in extracted mouse
livers (Figures 2C, S3).
Analyses of drug-inhibition of PbGFP-Luccon liver stage
development by luminescence measurements
Having established that liver stage infection can be accurately
and conveniently measured in vitro and in vivo by assessing the
luminescence of PbGFP-Luccon-infected cells or mice livers, we
decided to investigate the suitability of this method for the
evaluation of anti-plasmodial drugs. The inhibition of in vitro
development by drugs was determined by measurement of
luminescence of PbGFP-Luccon-infected hepatoma cells main-
tained in 24-well plates and incubated with serial dilutions of five
different drugs known to inhibit liver stage development
(Figures 3A&B). Primaquine [47] tafenoquine [48] genistein
[25], lopinavir [24] and saquinavir [24] were added to Huh7
cells 1 h before addition of Pb-GFP-Luccon sporozoites and
luminescence was measured 44 h later with a microplate reader.
In samples treated with the highest drug concentrations, known to
completely block liver stage development, the luminescence values
are low and almost identical to background ranging consistently
from 20 to 350 RLU (mean of 104; sd 119). In contrast, in drug-
free control samples luminescence values ranged between 46104
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Figure 2. Analysis of in vivo liver stage development by determination of luciferase expression (luminescence). A. Representative
rainbow images of luminescence in livers of live mice at different time points after injection of 16105 sporozoites. Rainbow images show the relative
levels of luminescence ranging from low (blue), to medium (green), to high (yellow/red). B. Luminescence levels (photons/sec) of livers in whole mice
at different time points after infection with 16105 sporozoites (n = 4). Photon counts from whole body imaging are expressed as the percentage of
the photon counts of mice at 44 h after infection ( = RLU %). C. Distribution of luminescence signals in the livers of live mice and in extracted livers of
the same mice at 44 h after infection with 16103 (left) or 16104 (right) of sporozoites. D. Luminescence levels (photons/sec) of whole bodies and
extracted livers of mice 44 h after inoculation of different numbers of sporozoites. Photon counts are expressed as the percentage of the photon
counts of whole body of mice at 44 h infected with 105 sporozoites ( = RLU %). E. Correlation between luminescence values as measured by the
Lumina system of whole body and dissected livers and of P. berghei 18S rRNA levels as determined by qRT-PCR of dissected livers that are infected
with different numbers of sporozoites. The percentage of growth is normalized to the highest reading within each experiment. See Table S2 for the
correlation coefficient data of the two-tailed Spearman’s rho test. F. The left panel shows the 3D-imaging of luminescence signals (3D tomography
and source reconstruction) in a mouse at 44 h after infection with 5 to 10 mosquito bites as measured with the IVIS 3D Series system. The brown/red
spots (white arrows) indicate the origin of highest luminescence intensity in the body. These spots are located in the liver as shown by overlaying
with a digital mouse atlas to obtain anatomical reference points (see also Supplementary Movie S1 of mouse 1). The right panel shows the same
mouse and its extracted liver (imaged at both sides) imaged with the 2D-IVIS100 imaging system. Numbers in the images represent the number of
luminescent spots identified. The number of spots (13) in the whole body is determined by the 3D analysis as can be seen in Supplementary Movie
S1.
doi:10.1371/journal.pone.0007881.g002
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Figure 3. Drug-inhibition of liver stage development determined by measurement of luciferase expression (luminescence). A.
Inhibition of in vitro liver stage development by primaquine (left panel) by measuring luminescence levels (RLU) in samples of Huh7 cells 44 h after
infection of the cells with 36104 PbGFP-Luccon sporozoites. The right panel shows the inhibition of liver stage development by primaquine as
determined by both luminescence measurements and qRT-qPCR analysis. The percentage of growth is defined by the RLU values and by the
amounts of P. berghei 18S rRNA levels, respectively. Luminescence levels were measured using a Tecan microplate reader. B. Inhibition of in vitro liver
stage development by tafenoquine, lopinavir, sanquinavir and genistein, as determined by measuring luciferase luminescence levels (RLU) in samples
of Huh7-infected cells 44 h after infection of the cells with 36104 PbGFP-Luccon sporozoites. Luminescence levels were measured using a microplate
reader. C. Inhibition of in vivo liver stage development by primaquine and tafenoquine as determined by measuring luminescence levels (photons/
sec) in live mice at 44 h after infection of the mice by the bite of 5 infected mosquitoes. Luminescence levels were determined by direct imaging of
whole bodies using the IVIS100 system.
doi:10.1371/journal.pone.0007881.g003
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to 76104 RLU (mean 56104; sd 96103) in the different
experiments (Figure 3A&B). Primaquine’s IC50 value as deter-
mined by luminescence intensity correlated well with the value
obtained by standard qRT-PCR methods (Figure 3A). Complete
inhibition with primaquine and tafenoquine was observed at
concentrations of 100 mM and 30 mM, respectively, which
correspond to inhibitory concentrations reported in the literature
for primaquine (261027 to 561025 M) and tafenoquine
361027 M [23,47,49]. Genistein, lopinavir and saquinavir
concentrations that inhibited liver stage development, quantified
by the decrease in luminescence intensities are also in good
agreement with previously reported inhibitory concentrations for
these compounds that were determined by direct counting of liver
stages or by qRT-PCR (Figure 3B)[24,25].
Analysis of in vivo inhibition of liver stage development by
luminescence measurements was performed using primaquine and
tafenoquine. Mice were treated 5 times with different doses of
these drugs starting one day before infection with PbGFP-Luccon
and the last dose at 29 h after infection. Mice were infected by the
bites of 5 infected mosquitoes and luminescence levels were
determined 44 h later. Luminescence values of untreated, control
mice, ranged between 26108 and 26109 p/s (mean 16109; sd
56108). No detectable luminescence signal was observed in mice
treated with 10–40 mg/kg body weight of primaquine, indicating
complete inhibition of parasite growth (Figure 3C). Indeed,
analysis of these mice 5–9 days after infection showed no
detectable parasites in peripheral blood, whereas control mice
developed normal blood infections with parasitemias ranging
between 0.1 and 3% at day 4 post-infection. In mice treated with 1
and 5 mg/kg body weight of primaquine, 3 out of 6 mice showed
a low level of luminescence ranging between 16108 and 56108 p/
s (mean 36108; sd 26108) at 44 h while the remaining 3 mice were
negative. Five of these mice developed a blood stage parasitemia
that was delayed by two days compared to the control mice
(parasitemia of 0,5 to 3% at day 6 after infection), indicating a
100-fold inhibition of liver stage development. All mice treated
with 10 or 20 mg/kg of tafenoquine were luminescence negative
at 44 h and did not develop blood stage infection (Figure 3C). The
complete inhibition of liver stage development by primaquine and
tafenoquine at doses of 10 mg/kg body weight and higher is in
agreement with the inhibitory doses reported in the literature
[25,50,51].
Discussion
Rodent malaria parasites are frequently used for the identifi-
cation and characterization of new anti-malarial drugs [17–
20,25,50,52,53]. These parasites are used in initial drug and small
molecule inhibitor (SMI) screens in order to determine their in vivo
anti-malarial activity in cultured cells and in mice. In comparison
to the blood-stage parasite SMI screening assays [19] the screening
and identification of agents that inhibit Plasmodium development in
the liver is considerably more complex. Quantitative analysis of
liver stage development both in cultured liver cells, in vitro, and in
small laboratory animals, in vivo, is hampered by the low levels of
parasite infection as well as the complicated, time consuming and
expensive methods required to monitor parasite development,
such as qRT-PCR or direct counting of liver stages [21–23,26,27]
and RNA hybridization [28,29]. We have recently shown that
transgenic rodent parasites expressing luciferase are useful
reagents to determine parasite load and bio-distribution of blood
stages in live mice using in vivo imaging [36,37]. We have also used
these parasites to assess the sensitivity of blood stages to drugs by
measuring luminescence using a microplate reader based assay
[19]. We now show that luminescence assays can also be used for
the quantitative analysis of liver infection and that the results of
these assays closely correlate to standard analysis methods (i.e.
qRT-PCR). The transgenic parasite used in these assays, PbGFP-
Luccon, expresses luciferase under the control of the strong and
constitutive eef1a promoter. This promoter has previously been
shown to drive expression of reporter proteins in growing and
dividing stages throughout the parasite’s life-cycle [39]. The strong
increase in reporter gene expression using this promoter from
sporozoite-hepatocyte invasion to mature liver schizont is matched
with reporter gene expression from merozoite-erythrocyte invasion
to schizogony. The significant increase in luminescence 5–
10 hours after sporozoite infection of hepatocytes, as compared
to cultures incubated with sporozoites whose ability to invade liver
cells is impaired (i.e. treated with cytochalasin-D), shows that
luciferase production starts rapidly after invasion of the hepato-
cyte. We reproducibly observed a clear increase in luminescence
48 hours post infection in hepatocyte cultures infected with as few
as 56103 sporozoites, compared to uninfected control wells. This
sensitivity of the luminescence assays with low sporozoite numbers
in combination with the early detection of luciferase expression
offers unique possibilities for large scale screenings of inhibitors of
parasite liver stage development, with the potential for automa-
tion, using microplate assays. The use of such assays would confer
the same advantage currently only available to drug screening
against blood stage parasites [19].
Despite the expression of luciferase during the early stages of
parasite development within hepatocytes, we were not able to
detect luminescence signals in live mice during the first 20 hours of
infection, even at the highest infection dose of 16105 sporozoites.
To investigate whether the sensitivity of detection of the young
liver stages could be increased, we analysed a transgenic parasite
line (mutant RMgm-152 in www.pberghei.eu) that expresses
PbGFP-Luciferase under the control of the promoter of the
circumsporozoite protein (CS; PB001026.00.0). The sporozoite
stage of these reporter parasites strongly expresses the reporter
fusion protein as visualised by GFP-fluorescence intensity; but we
were still unable to detect sporozoites in the liver by in vivo
imaging, although we were able to detect sporozoites in the skin at
the site of biting when we measured mice directly after mosquito
feeding (data not shown). Although we were not able to detect the
young liver stages, the more mature liver stages were readily
detected 30 h post infection of the mice, even after infection with a
sporozoite dose as low as 16103 sporozoites. The 30–48 h period
corresponds to the phase of schizogony during which a single
parasite can produce more than 16104 daughter merozoites [54].
It is known that laboratory mice are relatively insensitive to
infection with P. berghei sporozoites and therefore the sensitivity of
in vivo imaging might even be higher if the reporter line were made
in another rodent malaria parasite, P. yoelii, to which mice are
more sensitive. When blood stage infections were analysed in mice
that resulted from infections initiated with 16103 sporozoites we
calculated that the luminescence signal measured at 48 h was the
result of only 1–5 schizonts. This is based on the assumption that
the parasite multiplication rate in erythrocytes is 10-fold every
24 hours [55] and that each liver schizont contains between
26103 and 16104 merozoites. The detection of localised spots of
luminescence in dissected livers indicates that the in vivo imaging
enables detection to the level of a single infected hepatocyte
containing a mature liver schizont. However, the total luminescent
intensity of extracted livers was lower than the luminescence
intensity of livers determined by imaging of live mice. This was
initially surprising because the expected quenching of lumines-
cence by tissues in live mice would be absent when the isolated
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organ was examined. However, the lower values obtained from
dissected livers are most likely the result of the rapid uptake and
possibly metabolism of luciferin [56] during the time required to
collect the liver.
It has recently been shown that mature liver schizonts produce
so called merosomes, packets of 100–200 merozoites surrounded
by the host cell membrane [57,58]. The possibility to detect
bioluminescence signals of individual liver schizonts might also
offer opportunities to analyse the process of merosome formation
as well as merosome migration after their release from the infected
hepatocyte. Merosomes are released in the blood circulating and
appear to specifically accumulate in the lungs whereupon they
burst open and merozoites are released and invade red blood cells
[58]. It would therefore be interesting to see if the methodologies
in this study can be adapted to also image the merosomes in the
liver and then in isolated lungs or in lungs of whole bodies of
animals to add to our understanding of merosome biology.
The similar numbers of luminescence spots detected in dissected
livers and in living mice (analysed by 3D imaging) also supports the
notion that in vivo imaging can detect an individual mature liver
schizont. However, in dissected livers there were several
luminescence spots that were detected at only on one side of the
liver and by combining whole body imaging and imaging of
dissected livers we found that a minor fraction of the schizonts was
undetectable by either of the two methods. In addition, a few mice
treated with non-curative doses of primaquine showed no
luminescence signals but developed a (delayed) blood stage
infection. These observations indicate that small numbers of liver
schizonts can be missed with whole body imaging, although in the
case of primaquine treatment the absence of a luminescence signal
might also be due to delayed development of the liver schizonts.
To investigate whether we could increase the sensitivity of
detection of mature liver schizonts we have separately analysed
a different transgenic line which expresses luciferase under the
control of the ama1 promoter (PB000821.01.0) [36]; mutant
RMgm-30 in www.pberghei.eu). The ama1 gene encodes the
micronemal protein, AMA1, in merozoites and it was our
contention that since very large numbers of merozoites are
produced in each liver schizont we could expect a high luciferase
signal. Surprisingly, using similar sporozoite numbers as used with
our ef1aa promoter line, we measured a significantly lower
luminescence signal, even in measurements that were taken at
later time points (48–60 h) after infection (data not shown).
The analysis of drug-inhibition of parasite liver stage develop-
ment by in vivo imaging offers clear advantages over standard
qRT-PCR analysis of dissected livers or analysing the dynamics of
the blood stage infection subsequent to liver infection. qRT-PCR
analysis is both time consuming and expensive whereas the
analysis of subsequent blood stage infections cannot easily
discriminate the effect of the drugs on liver stage and/or resulting
blood stage infections. In contrast, in vivo imaging is rapid and
simple and allows, within the same animal, to measure both the
specific inhibition of liver stage development by an inhibitor or
drug and its subsequent effects on the blood stages. The analysis by
in vivo imaging has the advantage in that analysis does not require
sacrificing the experimental animal and thereby reduces the
number of animals required for experimentation since multiple
measurements can be made in the same animal over time.
Moreover, it also has the advantage that it minimizes the
biological variation within the study [59,60,60]. The in vivo
analysis of drug sensitivity of liver stages to primaquine and
tafenoquine was performed with mice that were infected by the
bite of only five infected mosquitoes. All the control mice in these
experiments (i.e. infections in the absence of drug) show a strong
luminescence signal at 48 h after infection. These experiments
demonstrate that in vivo drug-sensitivity assays are not dependent
on the injection of mice with high numbers of sporozoites, which
requires time-consuming manual dissection from mosquito
salivary glands. The sensitivity of in vivo imaging therefore greatly
simplifies the procedure of in vivo drug-sensitivity testing. An
additional feature of the reporter protein luciferase that may be of
great benefit is that it has a relatively short half-life and therefore
only allows the detection of live parasites, thereby avoiding errors
potentially associated with the counting of dead liver parasites (as
may occur with qRT-PCR experiments). The imaging assays
described in this paper can also be used for the screening and
analysis of parasite mutants for aberrant liver stage development.
Moreover, these can be used to analyse liver stage development in
challenge studies of mice that are immunized with either subunit
vaccines against sporozoites/liver stage molecules or with
genetically attenuated sporozoites. In conclusion, quantitative
analysis of liver stage development by real-time imaging should
greatly aid the validation of drugs and vaccines that act against the
liver stages of the Plasmodium.
Supporting Information
Supplementary Table S1
Found at: doi:10.1371/journal.pone.0007881.s001 (0.10 MB
DOC)
Supplementary Table S2
Found at: doi:10.1371/journal.pone.0007881.s002 (0.06 MB
DOC)
Supplementary Figure S1 Analyis of sporozoite motility, cell
traversal and infectivity of PbGFP-Luccon A. Representative
immunofluorescence staining with anti-PbCSP ([61]) of the trails
produced by PbGFP-Luccon (left) and wild type sporozoites
(right). Characteristic circles of gliding motility are observed in
PbGFP-Luccon sporozoites. B. Cell traversal ability of wild type
and PbGFP-Luccon sporozoites as determined by FACS counting
of Dextran positive Huh7 cells. FACS counting was performed 3 h
after infection of Huh7 cells with 66104 sporozoites. Uninfected:
hepatocytes cultured in the presence of Dextran but without the
addition of sporozoites. C. Infection of Huh7 cells on coverslips
using 36104 PbGFP-Luccon (left) and PbGFPcon [39] (right)
sporozoites. After fixing and staining, similar numbers of
exoerythrocytic forms are observed at 48 h post infection for both
parasites. D. qRT-PCR quantification of in vitro invasion of
HepG2 cells by wild type and PbGFP-Luccon at 24 h (black bars)
and at 45 h post invasion (white bars). Cyto D: cultures with
cytochalasin-D. E. qRT-PCR quantification of liver invasion in
mice of wild type and PbGFP-Luccon sporozoites. qRT-PCR was
performed on material from livers collected at 43 h after infection
of the mice with 36104 sporozoites. The pre-patent period,
defined as the days between injection of sporozoites and a blood
infection with a parasitemia of 0.5–2%, was 4.2 days (range 4–5
days) for PbGFP-Luccon compared to 4.4 days (range 4–5) for
wild type parasites after injection of 16104 sporozoites. After
injection of 16104 sporozoites the pre-patent periods were 5.3
days (range 5–6) for PbGFP-Luccon and 5.5 days (range 5–6) for
wild type parasites.
Found at: doi:10.1371/journal.pone.0007881.s003 (0.28 MB TIF)
Supplementary Figure S2 Analysis of in vitro liver stage
development in HepG2 cells by determination of luciferase
expression (luminescence). A. Relationship between the numbers
of sporozoites used to infect hepatocyte cultures and the
luminescence produced by the liver stages at 24, 30 and 48 h
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after infection. Luminescence levels were measured using the
Lumina system (Photons/sec). B. Relationship between the
numbers of sporozoites used to infect hepatocyte cultures and
the luminescence produced by the liver stages at 24, 30 h, 48 h
after infection. Luminescence levels were measured using the
Lumina system (Photons/sec) and a Wallac microplate reader
(Relative light units, RLU), respectively. C. Relationship between
the numbers of sporozoites used to infect hepatocyte cultures and
the luminescence produced by the liver stages at 30 after infection.
Luminescence levels were measured using the Lumina system
(Photons/sec) and a Wallac microplate reader (Relative light unit,
RLU), respectively. D. Correlation between luminescence values
and 18S rRNA levels. Luminescence values were determined using
the Lumina system and the Wallac microplate reader (see C). P.
berghei 18S rRNA levels were determined by qRT-PCR of
hepatocyte cultures infected with different numbers of sporozoites.
The percentage of growth is normalized to the highest reading
within each experiment. See Table S1 for the correlation
coefficient data of the two-tailed Spearman’s rho test.
Found at: doi:10.1371/journal.pone.0007881.s004 (0.15 MB TIF)
Supplementary Figure S3 Imaging of whole bodies and
dissected livers (IVIS100) of mice at 44 h after infection by
16103 (A) or 16104 sporozoites (B). Dissected livers were imaged
at both sides. Numbers in the pictures of Panel A show the number
of luminescent spots identified.
Found at: doi:10.1371/journal.pone.0007881.s005 (0.68 MB TIF)
Supplementary Figure S4 A. Whole body imaging (IVIS100)
of two representative mice during the period of 24–68 h after
infection by bites of 20 infected mosquitoes, showing a strong
increase of luminescence intensity of the liver during the period of
30–44 h after infection and a subsequent decrease after 52 h in the
liver. The strong increase in luminescence of the whole body at
68 h is the result of the dissemination of the liver merozoites
released into the bloodstream and subsequent invasion of
erythrocytes. Rainbow images show the relative level of lumines-
cence ranging from low (blue), to medium (green), to high (yellow/
red). B. Imaging of whole bodies and extracted livers (IVIS100) of
Wistar rats at 44 h after infection by bites of 1 or 5 infected
mosquitoes. Extracted livers were measured at both sides (a, b) and
lobes (c) and small sliced liver pieces (d) were analysed for
additional luminescence spots. Numbers in the images represent
the number of luminescent spots identified.
Found at: doi:10.1371/journal.pone.0007881.s006 (0.46 MB TIF)
Supplementary Figure S5 A. Source reconstruction of 3D
whole body imaging of three mice at 44 h after infection by bites
of 5–10 infected mosquitoes. Eleven luminescent sources are
detected in mouse 3 (M3), one in mouse 5 (M5) and none in mouse
4 (M4). See also Supplementary Movies 2 and 3 corresponding to
mouse 3 and 5 respectively. B. 2D-imaging of the extracted livers
of the mice shown in panel A. Livers were imaged at both sides
using the IVIS Spectrum system. Numbers in the images represent
the number of luminescent spots identified. Rainbow images show
the relative level of luminescence ranging from low (blue), to
medium (green), to high (yellow/red).
Found at: doi:10.1371/journal.pone.0007881.s007 (0.74 MB TIF)
Movie S1
Found at: doi:10.1371/journal.pone.0007881.s008 (2.29 MB AVI)
Movie S2
Found at: doi:10.1371/journal.pone.0007881.s009 (0.49 MB AVI)
Movie S3
Found at: doi:10.1371/journal.pone.0007881.s010 (0.46 MB AVI)
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